https://m2.mtmt.hu/ hun 2026-09-20 17:51 JournalArticle 34877420 VALIDATED true Cited By :1 Export Date: 7 October 2024 Correspondence Address: Révész, M.; Multidisciplinary Head and Neck Cancer Center, Hungary; email: revesz.monika@oncol.hu Correspondence Address: Takácsi-Nagy, Z.; Center of Radiotherapy, Hungary; email: takacsi.zoltan@oncol.hu Chemicals/CAS: formaldehyde, 50-00-0; Biomarkers, Tumor; Enhancer of Zeste Homolog 2 Protein; EZH2 protein, human; Tumor Suppressor Protein p53 0 false 2026-05-23T20:51:38.802+0000 2026-02-26T11:43:49.161+0000 2024-05-27T06:03:46.582+0000 true 10081340 Pirmann Tamás /api/admin/10081340 Admin Pirmann Tamás (OOI addmin5, admin) true 2026-02-26T11:43:48.827+0000 2024-09-16T13:53:01.685+0000 true 10062062 Gere Tamásné /api/admin/10062062 Admin Gere Tamásné (SE_KK_Admin5_GT, admin) true 10062062 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Révész, Mónika true true /api/journal/10003252 REVIEWED INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 true false 10003252 false 10003252 true 1661-6596 1422-0067 Journal FOREIGN 25 10 5250 5250 12 2024 EZH2 (Enhancer of zeste homolog 2) promotes tumor growth and survival through numerous mechanisms and is a promising target for novel therapeutic approaches. We aimed to characterize the expression of EZH2 in the tumors of young head-and-neck squamous cell cancer (HNSCC) patients in comparison with the general HNSCC patient population. We used formalin-fixed, paraffin-embedded tissue blocks from 68 random young HNSCC patients (≤39 years, median age: 36 years; diagnosed between 2000 and 2018), which were compared with the samples of 58 age- and gender-matched general HNSCC subjects (median age: 62 years; all diagnosed in the year 2014). EZH2 and p53 expression of the tumors was detected using immunohistochemical staining. Lower EZH2 expression was found to be characteristic of the tumors of young HNSCC patients as opposed to the general population (median EZH2 staining intensity: 1 vs. 1.5 respectively, p < 0.001; median fraction of EZH2 positive tumor cells: 40% vs. 60%, respectively, p = 0.003, Mann–Whitney). Cox analysis identified a more advanced T status (T3-4 vs. T1-2), a positive nodal status, and alcohol consumption, but neither intratumoral EZH2 nor p53 were identified as predictors of mortality in the young patient group. The lower EZH2 expression of young HNSCC patients’ tumors discourages speculations of a more malignant phenotype of early-onset tumors and suggests the dominant role of patient characteristics. Furthermore, our results might indicate the possibility of an altered efficacy of the novel anti-EZH2 therapies in this patient subgroup. Funding 2040516 /api/funding/2040516 (National Tumor Biology Laboratory (2022–2.1.1-NL-2022-00010))) false true Funding 2040517 /api/funding/2040517 Hungarian Thematic Excellence Program((TKP2021-EGA-44)) false true true 2024 true true true false true false GOLD 2026-05-23 false http://www.mdpi.com/journal/ijms 6 0 6 6 0 6 6 5 3 6 6 6 6 6 0 0 6 6 6 6 0 2 2 Folyóiratcikk Journal Article 24 6 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2024 0 2 2 2 2 2025 0 3 3 3 3 2026 0 1 1 1 1 D1 false false false false 2024-06-03T11:08:25.361+0000 Onkológiai Tanszék (SE / AOK / K); Országos Onkológiai Intézet; Patológiai, Igazságügyi és Biztosítási Orvostan... (SE / AOK / I) 6 12 3 7 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 116782142 /api/authorship/116782142 Révész, Mónika ✉ [Révész, Mónika (Fül-orr-gégészet), szerző] Országos Onkológiai Intézet 1 0.143 true false true Author 10028039 /api/author/10028039 Révész Mónika (Fül-orr-gégészet) Révész Mónika true 10028039 true Révész Mónika true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116782143 /api/authorship/116782143 Oberna, Ferenc [Oberna, Ferenc (Arc- és állcsonts...), szerző] Országos Onkológiai Intézet 2 0.143 false false false Author 10044886 /api/author/10044886 Oberna Ferenc (Arc- és állcsontsebészet, fül-orr-gégészet) Oberna Ferenc true 10044886 true Oberna Ferenc true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116782144 /api/authorship/116782144 Slezák, András 3 0.14285715 false false false Slezák András true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116782145 /api/authorship/116782145 Tóth, Erika [Tóth, Erika (patológia), szerző] Országos Onkológiai Intézet 4 0.143 false false false Author 10062288 /api/author/10062288 Tóth Erika (patológia) Tóth Erika true 10062288 true Tóth Erika true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116782146 /api/authorship/116782146 Ferenczi, Örs [Ferenczi, Örs (Sugárterápia), szerző] Országos Onkológiai Intézet 5 0.143 false false false Author 10085309 /api/author/10085309 Ferenczi Örs (Sugárterápia) Ferenczi Örs true true Ferenczi Örs true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116782147 /api/authorship/116782147 Kenessey, István [Kenessey, István (Patológia, onkológia), szerző] Országos Onkológiai Intézet; Patológiai, Igazságügyi és Biztosítási Orvostan... (SE / AOK / I) 6 0.143 false false false Author 10017547 /api/author/10017547 Kenessey István (Patológia, onkológia) Kenessey István true 10017547 true Kenessey István true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 116782148 /api/authorship/116782148 Takácsi-Nagy, Zoltán ✉ [Takácsi-Nagy, Zoltán (Sugárterápia), szerző] Országos Onkológiai Intézet; Onkológiai Tanszék (SE / AOK / K) 7 0.143 false true true Author 10013883 /api/author/10013883 Takácsi-Nagy Zoltán (Sugárterápia) Takácsi-Nagy Zoltán true 10013883 true Takácsi-Nagy Zoltán true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 26243322 /api/publicationidentifier/26243322 DOI: 10.3390/ijms25105250 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.3390/ijms25105250 https://doi.org/10.3390/ijms25105250 false true PublicationIdentifier 26414306 /api/publicationidentifier/26414306 WoS: 001234687200001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001234687200001 https://www.webofscience.com/wos/woscc/full-record/001234687200001 true true PublicationIdentifier 26313258 /api/publicationidentifier/26313258 Scopus: 85194218868 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85194218868 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85194218868 true true PublicationIdentifier 26243427 /api/publicationidentifier/26243427 PubMed: 38791289 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 38791289 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38791289&dopt=Abstract false true PublicationIdentifier 31546295 /api/publicationidentifier/31546295 Egyéb URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85194218868&doi=10.3390%2Fijms25105250&partnerID=40&md5=396bfc57537bba6e1da1c23f276217c8 PlainSource 40 /api/publicationsource/40 Egyéb URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true NONE IDENTICAL https://www.scopus.com/inward/record.uri?eid=2-s2.0-85194218868&doi=10.3390%2Fijms25105250&partnerID=40&md5=396bfc57537bba6e1da1c23f276217c8 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85194218868&doi=10.3390%2Fijms25105250&partnerID=40&md5=396bfc57537bba6e1da1c23f276217c8 false true SjrRating 11489344 /api/sjrrating/11489344 sjr:D1 (2024) Scopus - Organic Chemistry INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 18 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1605 /api/classificationexternal/1605 Scopus - Organic Chemistry true 1605 true D1 DIRECT true true Reference 53402544 /api/reference/53402544 1. Johnson 2020: Head and Neck Squamous Cell Carcinoma., Nat. Rev. Dis. Primer, 6, p. 92, DOI: 10.1038/s41572-020-00224-3 1 10.1038/s41572-020-00224-3 false true Reference 53402545 /api/reference/53402545 2. Sung 2021: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries., CA. Cancer J. Clin., 71, p. 209, DOI: 10.3322/caac.21660 2 10.3322/caac.21660 false true Reference 53402546 /api/reference/53402546 3. Zhao 2023: Global Trends in Incidence, Death, Burden and Risk Factors of Early-Onset Cancer from 1990 to 2019., BMJ Oncol., 2, p. e000049, DOI: 10.1136/bmjonc-2023-000049 3 10.1136/bmjonc-2023-000049 false true Reference 53402547 /api/reference/53402547 4. Coccia 2018: Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology., J. Natl. Compr. Cancer Netw., 16, p. 66, DOI: 10.6004/jnccn.2018.0001 4 10.6004/jnccn.2018.0001 false true Reference 53402548 /api/reference/53402548 5. Gamez 2018: Treatment Outcomes of Squamous Cell Carcinoma of the Oral Cavity in Young Adults., Oral Oncol., 87, p. 43, DOI: 10.1016/j.oraloncology.2018.10.014 5 10.1016/j.oraloncology.2018.10.014 false true Reference 53402549 /api/reference/53402549 6. Oberna 2023: The Characteristics of Head and Neck Squamous Cell Cancer in Young Adults: A Retrospective Single-Center Study., Pathol. Oncol. Res., 29, p. 1611123, DOI: 10.3389/pore.2023.1611123 6 10.3389/pore.2023.1611123 false true Reference 53402550 /api/reference/53402550 7. Panda, S., Mohanty, N., Panda, S., Mishra, L., Gopinath, D., Sahoo, A., Nagraj, S.K., and Lapinska, B. (2022). Are Survival Outcomes Different for Young and Old Patients with Oral and Oropharyngeal Squamous Cell Carcinoma? A Systematic Review and Meta-Analysis. Cancers, 14., DOI: 10.3390/cancers14081886 7 10.3390/cancers14081886 false true Reference 53402551 /api/reference/53402551 8. Kanwal 2012: Epigenetic Modifications in Cancer., Clin. Genet., 81, p. 303, DOI: 10.1111/j.1399-0004.2011.01809.x 8 10.1111/j.1399-0004.2011.01809.x false true Reference 53402552 /api/reference/53402552 9. Zhou 2020: Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti–PD-1 Resistance in Head and Neck Cancer., Clin. Cancer Res., 26, p. 290, DOI: 10.1158/1078-0432.CCR-19-1351 9 10.1158/1078-0432.CCR-19-1351 false true Reference 53402553 /api/reference/53402553 10. Bradley 2019: PRC2-Mediated MHC-I Silencing Drives Immune Evasion., Nat. Rev. Cancer, 19, p. 664, DOI: 10.1038/s41568-019-0219-4 10 10.1038/s41568-019-0219-4 false true Reference 53402554 /api/reference/53402554 11. Peng 2015: Epigenetic Silencing of TH1-Type Chemokines Shapes Tumour Immunity and Immunotherapy., Nature, 527, p. 249, DOI: 10.1038/nature15520 11 10.1038/nature15520 false true Reference 53402555 /api/reference/53402555 12. Lin 2023: The Heightened Importance of EZH2 in Cancer Immunotherapy., Cancer Screen. Prev., 2, p. 117 12 false true Reference 53402556 /api/reference/53402556 13. Zhao 2019: EZH2 Regulates PD-L1 Expression via HIF-1α in Non-Small Cell Lung Cancer Cells., Biochem. Biophys. Res. Commun., 517, p. 201, DOI: 10.1016/j.bbrc.2019.07.039 13 10.1016/j.bbrc.2019.07.039 false true Reference 53402557 /api/reference/53402557 14. Papale 2018: EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers., Front. Pediatr., 6, p. 328, DOI: 10.3389/fped.2018.00328 14 10.3389/fped.2018.00328 false true Reference 53402558 /api/reference/53402558 15. Mahara 2016: Molecular Switch of EZH2 in Hypoxia., Cell Cycle, 15, p. 3007, DOI: 10.1080/15384101.2016.1215699 15 10.1080/15384101.2016.1215699 false true Reference 53402559 /api/reference/53402559 16. Chang 2012: The Role of EZH2 in Tumour Progression., Br. J. Cancer, 106, p. 243, DOI: 10.1038/bjc.2011.551 16 10.1038/bjc.2011.551 false true Reference 53402560 /api/reference/53402560 17. Kovalchuk, I., and Kovalchuk, O. (2016). Genome Stability, Academic Press., DOI: 10.1016/B978-0-12-803309-8.00001-X 17 10.1016/B978-0-12-803309-8.00001-X false true Reference 53402561 /api/reference/53402561 18. Bachmann 2006: EZH2 Expression Is Associated with High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast., J. Clin. Oncol., 24, p. 268, DOI: 10.1200/JCO.2005.01.5180 18 10.1200/JCO.2005.01.5180 false true Reference 53402562 /api/reference/53402562 19. Fan, K., Zhang, B., Han, D., and Sun, Y. (2023). EZH2 as a Prognostic-Related Biomarker in Lung Adenocarcinoma Correlating with Cell Cycle and Immune Infiltrates. BMC Bioinform., 24., DOI: 10.1186/s12859-023-05271-7 19 10.1186/s12859-023-05271-7 false true Reference 53402563 /api/reference/53402563 20. Honrado 2017: The Role of EZH2 in Overall Survival of Colorectal Cancer: A Meta-Analysis., Sci. Rep., 7, p. 13806, DOI: 10.1038/s41598-017-13670-z 20 10.1038/s41598-017-13670-z false true Reference 53402564 /api/reference/53402564 21. Nienstedt 2018: EZH2 Overexpression in Head and Neck Cancer Is Related to Lymph Node Metastasis., J. Oral Pathol. Med., 47, p. 240, DOI: 10.1111/jop.12673 21 10.1111/jop.12673 false true Reference 53402565 /api/reference/53402565 22. Wang, Y., Wang, F., Wang, S., Zhang, L., Fu, H., Sun, L., Wang, W., Liu, C., Ren, W., and Gao, L. p16 and p53 can Serve as Prognostic Markers for Head and Neck Squamous Cell Carcinoma. Int. Dent. J., 2023. in press., DOI: 10.1016/j.identj.2023.11.007 22 10.1016/j.identj.2023.11.007 false true Reference 53402566 /api/reference/53402566 23. Tang 2004: Activated p53 suppresses the histone methyltransferase EZH2 gene., Oncogene, 23, p. 5759, DOI: 10.1038/sj.onc.1207706 23 10.1038/sj.onc.1207706 false true Reference 53402567 /api/reference/53402567 24. Kolegova 2022: Early-Onset Oral Cancer as a Clinical Entity: Aetiology and Pathogenesis., Int. J. Oral Maxillofac. Surg., 51, p. 1497, DOI: 10.1016/j.ijom.2022.04.005 24 10.1016/j.ijom.2022.04.005 false true Reference 53402568 /api/reference/53402568 25. Wang 2010: Reduced DNA Repair Capacity for Removing Tobacco Carcinogen-Induced DNA Adducts Contributes to Risk of Head and Neck Cancer but Not Tumor Characteristics., Clin. Cancer Res., 16, p. 764, DOI: 10.1158/1078-0432.CCR-09-2156 25 10.1158/1078-0432.CCR-09-2156 false true Reference 53402569 /api/reference/53402569 26. Illmer 2013: Polymorphisms of DNA Repair Genes and Risk of Squamous Cell Carcinoma of the Head and Neck in Young Adults., Eur. Arch. Oto-Rhino-Laryngol., 270, p. 271, DOI: 10.1007/s00405-012-1993-8 26 10.1007/s00405-012-1993-8 false true Reference 53402570 /api/reference/53402570 27. Varambally 2002: The Polycomb Group Protein EZH2 Is Involved in Progression of Prostate Cancer., Nature, 419, p. 624, DOI: 10.1038/nature01075 27 10.1038/nature01075 false true Reference 53402571 /api/reference/53402571 28. Gan 2018: The Polycomb Group Protein EZH2 Induces Epithelial–Mesenchymal Transition and Pluripotent Phenotype of Gastric Cancer Cells by Binding to PTEN Promoter., J. Hematol. Oncol., 11, p. 9, DOI: 10.1186/s13045-017-0547-3 28 10.1186/s13045-017-0547-3 false true Reference 53402572 /api/reference/53402572 29. Huet 2017: EZH2 Alterations in Follicular Lymphoma: Biological and Clinical Correlations., Blood Cancer J., 7, p. e555, DOI: 10.1038/bcj.2017.32 29 10.1038/bcj.2017.32 false true Reference 53402573 /api/reference/53402573 30. Christofides 2016: Epigenetic Regulation of Cancer Biology and Anti-Tumor Immunity by EZH2., Oncotarget, 7, p. 85624, DOI: 10.18632/oncotarget.12928 30 10.18632/oncotarget.12928 false true Reference 53402574 /api/reference/53402574 31. Duan 2020: EZH2: A Novel Target for Cancer Treatment., J. Hematol. Oncol., 13, p. 104, DOI: 10.1186/s13045-020-00937-8 31 10.1186/s13045-020-00937-8 false true Reference 53402575 /api/reference/53402575 32. Castilho, R.M., Squarize, C.H., and Almeida, L.O. (2017). Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy. Int. J. Mol. Sci., 18., DOI: 10.3390/ijms18071506 32 10.3390/ijms18071506 false true Reference 53402576 /api/reference/53402576 33. Kidani 2009: High Expression of EZH2 Is Associated with Tumor Proliferation and Prognosis in Human Oral Squamous Cell Carcinomas., Oral Oncol., 45, p. 39, DOI: 10.1016/j.oraloncology.2008.03.016 33 10.1016/j.oraloncology.2008.03.016 false true Reference 53402577 /api/reference/53402577 34. Mochizuki, D., Misawa, Y., Kawasaki, H., Imai, A., Endo, S., Mima, M., Yamada, S., Nakagawa, T., Kanazawa, T., and Misawa, K. (2018). Aberrant Epigenetic Regulation in Head and Neck Cancer Due to Distinct EZH2 Overexpression and DNA Hypermethylation. Int. J. Mol. Sci., 19., DOI: 10.20944/preprints201810.0565.v1 34 10.20944/preprints201810.0565.v1 false true Reference 53402578 /api/reference/53402578 35. Chang 2016: EZH2 Is Associated with Poor Prognosis in Head-and-Neck Squamous Cell Carcinoma via Regulating the Epithelial-to-Mesenchymal Transition and Chemosensitivity., Oral Oncol., 52, p. 66, DOI: 10.1016/j.oraloncology.2015.11.002 35 10.1016/j.oraloncology.2015.11.002 false true Reference 53402579 /api/reference/53402579 36. Wu 2020: Data Mining Identifies Six Proteins That Can Act as Prognostic Markers for Head and Neck Squamous Cell Carcinoma., Cell Transplant., 29, p. 0963689720929308, DOI: 10.1177/0963689720929308 36 10.1177/0963689720929308 false true Reference 53402580 /api/reference/53402580 37. Argiris 2008: Head and Neck Cancer., Lancet Lond. Engl., 371, p. 1695, DOI: 10.1016/S0140-6736(08)60728-X 37 10.1016/S0140-6736(08)60728-X false true Reference 53402581 /api/reference/53402581 38. Idris 2016: Investigation of EZH2 Pathways for Novel Epigenetic Treatment Strategies in Oropharyngeal Cancer., J. Otolaryngol., 45, p. 54 38 false true Reference 53402582 /api/reference/53402582 39. Samaržija, I., Tomljanović, M., Novak Kujundžić, R., and Trošelj, K.G. (2022). EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies. Cancers, 14., DOI: 10.3390/cancers14194761 39 10.3390/cancers14194761 false true Reference 53402583 /api/reference/53402583 40. Mery 2023: Evaluation of Data Quality at the Hungarian National Cancer Registry, 2000-2019., Cancer Epidemiol., 82, p. 102306, DOI: 10.1016/j.canep.2022.102306 40 10.1016/j.canep.2022.102306 false true Reference 53402584 /api/reference/53402584 41. (2024, April 03). International Guide for Monitoring Alcohol Consumption and Related Harm. Available online: https://iris.who.int/handle/10665/66529. 41 false true /api/publication/34877420 Révész Mónika et al. EZH2 Expression in Head-and-Neck Squamous Cell Cancer in Young Patients. (2024) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 25 10<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10028039"><a href="/gui2/?type=authors&mode=browse&sel=10028039" target="_blank">Révész Mónika ✉ (<span class="authorship-author-name">Révész Mónika</span> <span class="authorAux-mtmt"> Fül-orr-gégészet</span>) </a> </span> <span class="author-affil">Országos Onkológiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10044886"><a href="/gui2/?type=authors&mode=browse&sel=10044886" target="_blank">Oberna Ferenc (<span class="authorship-author-name">Oberna Ferenc</span> <span class="authorAux-mtmt"> Arc- és állcsontsebészet, fül-orr-gégészet</span>) </a> </span> <span class="author-affil">Országos Onkológiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Slezák András </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10062288"><a href="/gui2/?type=authors&mode=browse&sel=10062288" target="_blank">Tóth Erika (<span class="authorship-author-name">Tóth Erika</span> <span class="authorAux-mtmt"> patológia</span>) </a> </span> <span class="author-affil">Országos Onkológiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10085309"><a href="/gui2/?type=authors&mode=browse&sel=10085309" target="_blank">Ferenczi Örs (<span class="authorship-author-name">Ferenczi Örs</span> <span class="authorAux-mtmt"> Sugárterápia</span>) </a> </span> <span class="author-affil">Országos Onkológiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10017547"><a href="/gui2/?type=authors&mode=browse&sel=10017547" target="_blank">Kenessey István (<span class="authorship-author-name">Kenessey István</span> <span class="authorAux-mtmt"> Patológia, onkológia</span>) </a> </span> <span class="author-affil">Országos Onkológiai Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai, Igazságügyi és Biztosítási Orvostani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10013883"><a href="/gui2/?type=authors&mode=browse&sel=10013883" target="_blank">Takácsi-Nagy Zoltán ✉ (<span class="authorship-author-name">Takácsi-Nagy Zoltán</span> <span class="authorAux-mtmt"> Sugárterápia</span>) </a> </span> <span class="author-affil">Országos Onkológiai Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Onkológiai Tanszék</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;34877420" target="_blank">EZH2 Expression in Head-and-Neck Squamous Cell Cancer in Young Patients</a></div> <div> <span class="journal-title">INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/1661-6596">1661-6596</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1422-0067">1422-0067</a>)</span>: <span class="journal-volume">25</span> <span class="journal-issue">10</span> <span class="page"> Paper 5250. 12 p. </span> <span class="year">(2024)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.3390/ijms25105250" target="_blank" href="https://doi.org/10.3390/ijms25105250"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001234687200001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001234687200001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85194218868" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85194218868"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="38791289" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38791289&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_NONE" title=" Nincs "> <a style="color:blue" title="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85194218868&doi=10.3390%2Fijms25105250&partnerID=40&md5=396bfc57537bba6e1da1c23f276217c8" target="_blank" href="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85194218868&doi=10.3390%2Fijms25105250&partnerID=40&md5=396bfc57537bba6e1da1c23f276217c8"> Egyéb URL </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Organic Chemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Spectroscopy&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Computer Science Applications&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Inorganic Chemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Physical and Theoretical Chemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Catalysis&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Molecular Biology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 6</span> | Független: 6 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 5 | Scopus jelölt:&nbsp;3 | WoS/Scopus jelölt:&nbsp;6 | DOI jelölt:&nbsp;6 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;34877420&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 2 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 34877420</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (National Tumor Biology Laboratory (2022–2.1.1-NL-2022-00010))), Hungarian Thematic Excellence Program((TKP2021-EGA-44)) </div> <div class="lastModified">Utolsó módosítás: 2026.02.26. 12:43 Pirmann Tamás (OOI admin4) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Cited By :1 Export Date: 7 October 2024 Correspondence Address: Révész, M.; Multidisciplinary Head and Neck Cancer Center, Hungary; email: revesz.monika@oncol.hu Correspondence Address: Takácsi-Nagy, Z.; Center of Radiotherapy, Hungary; email: takacsi.zoltan@oncol.hu Chemicals/CAS: formaldehyde, 50-0...</pre> </div></div>